Drug Profile
Tc 99m glucarate
Alternative Names: AMISCAN; Tc-99m-glucarate; Technetium glucarate; Technetium Tc 99m glucarateLatest Information Update: 03 Aug 2015
Price :
$50
*
At a glance
- Originator Molecular Targeting Technologies
- Developer DRAXIS Specialty Pharmaceuticals; Molecular Targeting Technologies
- Class Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Sugar acids; Technetium compounds
- Mechanism of Action Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute coronary syndromes
Most Recent Events
- 03 Aug 2015 No recent reports on development identified - Phase-II for Acute coronary syndromes (Diagnosis) in USA and Canada (IV)
- 05 Jan 2005 DRAXIS Pharma has merged with DRAXIMAGE to form DRAXIS Specialty Pharmaceuticals
- 25 Jul 2003 DRAXIMAGE and Bristol-Myers Squibb Imaging have extended and expanded their existing agreement in Canada